Supply of products by Novartis Vaccines and Diagnostics Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to regulate the supply and standards of therapeutic goods within the country, addressing issues related to the safety, quality, and efficacy of these goods. This legislation provides a comprehensive framework for the regulation of therapeutic goods, ensuring that they are appropriately controlled and that they meet acceptable standards before being made available to the public. The Therapeutic Goods Administration (TGA), under the Department of Health and Ageing, is the body responsible for enforcing this Act, ensuring that the therapeutic goods supplied in Australia are safe and of high quality. The policy objective of the Act is to protect public health by controlling the quality, safety, and efficacy of therapeutic goods available in the Australian market. In this specific case, the Act was invoked to provide a temporary exemption for certain labelling non-compliances of imported vaccines, thereby facilitating timely access to essential medical products while maintaining overall regulatory oversight.

Scope and Application

The Therapeutic Goods Act 1989 applies to therapeutic goods which include medicines, medical devices, blood and blood components, tissues, and contraceptives within Australia. This Act governs the regulation of therapeutic goods throughout the Commonwealth and ensures they meet safety, quality, and efficacy standards. The Act applies to various entities, including manufacturers, importers, suppliers, and distributors of therapeutic goods. The Therapeutic Goods Administration (TGA), a part of the Department of Health and Ageing, is responsible for administering the Act. In the specific context of the notice issued on 16 August 2013, Novartis Vaccines and Diagnostics Pty Ltd was granted a consent under sections 14 and 14A of the Act to supply certain meningococcal B vaccines into Australia, notwithstanding non-compliance with specific labelling requirements stipulated in Therapeutic Goods Order No. 69. This exemption is narrowly tailored to address the non-compliance of the syringe labels with certain clauses of TGO 69, while mandating adherence to all other labelling requirements. The exemption is subject to conditions ensuring the overall compliance and safety of the therapeutic goods supplied.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the "Act") are central to the legislation in question. Section 14 allows the Secretary to give consent for the supply of therapeutic goods that do not fully comply with certain legislative requirements. Section 14A specifies conditions under which such consent can be given. In this instance, the delegate of the Secretary has permitted the supply of BEXSERO, a multicomponent Meningococcal B vaccine, by Novartis Vaccines and Diagnostics Pty Ltd, despite the product labels not fully conforming to Therapeutic Goods Order No. 69 (TGO 69). Specifically, the syringe labels do not meet Clauses 3(2)(b) and (c) of TGO 69, which typically relate to specific labelling requirements for medicines. The obligations imposed by this consent under the Act require that the products in question must adhere to all labelling requirements of TGO 69, except for the specific non-compliance noted regarding the syringe labels. This means that while the vaccine can be supplied in Australia, the labelling must comply with all other relevant sections of TGO 69. This ensures that the products are still safe and correctly identified, while acknowledging the minor labelling discrepancies. Breaches of the conditions stipulated in section 15(1) of the Act can lead to various consequences. Under the Act, supplying non-compliant therapeutic goods can be considered an offence. If the products do not adhere to the specified conditions or if the company fails to comply with other labelling requirements not covered by this exemption, it could face legal penalties. The Act does not specify maximum penalties for this particular exemption; however, in general, penalties for breaches can include fines, imprisonment, or both, depending on the severity and nature of the breach. Additionally, ongoing non-compliance can lead to the revocation of the product's inclusion on the Australian Register of Therapeutic Goods (ARTG), effectively banning the product from the market.